Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

The Research Foundation for the State

Neither a doctor nor a teaching hospital

Research payments

$518,926

147 payments

Through program year 2024, The Research Foundation for the State is reported as receiving $518,926 in research payments, across 147 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $41,315 14
2023 Research $134,862 28
2022 Research $128,785 47
2021 Research $39,007 20
2020 Research $129,239 23
2019 Research $45,718 15

Breakdown

Who paid Research payments · program years 2019–2024
  1. Intercept Pharmaceuticals, Inc. $290,456 100 payments
  2. Chiesi USA, Inc. $60,124 14 payments
  3. Intercept Pharma Europe Ltd. $44,402 10 payments
  4. Lexicon Pharmaceuticals, Inc. $36,103 1 payment
  5. Neurocrine Biosciences, Inc. $28,301 9 payments
  6. Ferring International Pharmascience Center US $21,184 3 payments
  7. Becton, Dickinson and Company $12,606 1 payment
  8. Roche Products Limited $11,000 2 payments
  9. Pfizer Inc. $7,000 4 payments
  10. Jazz Pharmaceuticals Inc. $6,000 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $178,449 48 payments
  2. 1009742 $87,937 25 payments
  3. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $42,389 19 payments
  4. Efc15156 $36,103 1 payment
  5. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $28,701 7 payments
  6. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Nbi-98854 in Pediatric Subjects With Tourette Syndrome $28,301 9 payments
  7. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $26,082 18 payments
  8. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $15,950 2 payments
  9. A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing Efficacy, Safety, Dose-response of Quinagolide Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate-Severe Endometriosis-related Pain $12,925 2 payments
  10. SUNY catheter study $12,606 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record